Cat. No. 4368
Alternative Names: PF 02341066, PF 2341066
Chemical Name: 3-[(1R)-1-(2,6-Dichloro-3-fluorophe
Biological ActivityPotent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Selective for c-MET and ALK against >120 different kinases. Orally bioavailable.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Christensen et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol.Cancer Ther. 6 3314. PMID: 18089725.
Zou et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 4408. PMID: 17483355.
Cui et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J.Med.Chem. 54 6342. PMID: 21812414.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Crizotinib, supplier, c-MET, alk, anaplastic, lymphoma, kinases, antitumor, selective, potent, PF2341066, PF02341066
Find multiple products by catalog number
New Products in this Area
EphA4 receptor tyrosine kinase antagonist; neuroprotectivePD 90780
Inhibits NGF binding to p75NTRLM11A 31 dihydrochloride
Nonpeptide p75NTR ligand; neuroprotectiveEG 00229
Neuropilin 1 (NRP1) receptor antagonist; inhibits VEGFA binding to NRP1Toceranib
Potent PDGFR and VEGFR inhibitorNVP ADW 742
ATP-competitive inhibitor of IGF1RKRCA 0008
Potent Ack1 and ALK dual inhibitor; orally bioavailableDDR1-IN-1 dihydrochloride
Selective DDR1 inhibitor
December 16 - 18, 2014
Booth Number: 12